Insulin resistance directly adds to this scenario irrespective of changes in glucose levels, body weight, blood pressure and lipids [53]
Purwana, I
These are promising results, but the studys authors note that more research is needed, and clinicians must also consider potential adverse effects, evaluate the cost-effectiveness of these medications for each patient, and closely monitor for any improvement or worsening of eating disorders and related side effects. That hesitation is shared by the National Eating Disorder Association (NEDA), who published an opinion paper on GLP-1s and eating disorders in 2024, stating: While there is some evidence that GLP-1s can decrease the number of binge eating episodes for those with BED, little is known about the long term physical and psychological impact on those with eating disorders. How GLP-1s could also fuel eating disorders The same mechanisms that make these medications helpful for some could make them harmful for others
GLP-1 medications are a great option for many people, but they aren't right for everyone
Gallbladder-related events occurred in 2.6% of semaglutide vs 1.2% of placebo participants
While compounded medications are not FDA-approved (meaning they haven't undergone the full FDA approval pathway), the active pharmaceutical ingredients themselvessemaglutide and tirzepatideare FDA-recognized compounds
